Last reviewed 2026-05-22 · How we verify

Supportive care+Ripertamab

Air Force Military Medical University, China · Phase 3 active Small molecule Under review

Supportive care+Ripertamab is a tyrosine kinase inhibitor Small molecule drug developed by Air Force Military Medical University, China. It is currently in Phase 3 development for Advanced gastrointestinal stromal tumor (GIST) with a KIT or PDGFRA mutation, Advanced or metastatic melanoma with a KIT or PDGFRA mutation. Also known as: Test group 2.

Ripretinib targets and inhibits the activity of KIT and PDGFRA kinases, which are involved in the growth and spread of cancer cells.

Ripertamab is an antibody used in supportive care for Minimal Change Disease, as seen in clinical trials. It is typically combined with other treatments such as prednisone or tacrolimus, and its mechanism of action is as an antibody.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Supportive care+Ripertamab
Also known as	Test group 2
Sponsor	Air Force Military Medical University, China
Drug class	tyrosine kinase inhibitor
Target	KIT, PDGFRA
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

Ripretinib works by selectively binding to the ATP-binding pocket of the KIT and PDGFRA kinases, thereby inhibiting their activity and preventing the activation of downstream signaling pathways that promote cancer cell growth and survival. This leads to a reduction in tumor size and a delay in disease progression.

Approved indications

Advanced gastrointestinal stromal tumor (GIST) with a KIT or PDGFRA mutation
Advanced or metastatic melanoma with a KIT or PDGFRA mutation

Common side effects

Hypertension
Fatigue
Nausea

Key clinical trials

Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Supportive care+Ripertamab CI brief — competitive landscape report
Supportive care+Ripertamab updates RSS · CI watch RSS
Air Force Military Medical University, China portfolio CI

Frequently asked questions about Supportive care+Ripertamab

What is Supportive care+Ripertamab?

Supportive care+Ripertamab is a tyrosine kinase inhibitor drug developed by Air Force Military Medical University, China, indicated for Advanced gastrointestinal stromal tumor (GIST) with a KIT or PDGFRA mutation, Advanced or metastatic melanoma with a KIT or PDGFRA mutation.

How does Supportive care+Ripertamab work?

Ripretinib targets and inhibits the activity of KIT and PDGFRA kinases, which are involved in the growth and spread of cancer cells.

What is Supportive care+Ripertamab used for?

Supportive care+Ripertamab is indicated for Advanced gastrointestinal stromal tumor (GIST) with a KIT or PDGFRA mutation, Advanced or metastatic melanoma with a KIT or PDGFRA mutation.

Who makes Supportive care+Ripertamab?

Supportive care+Ripertamab is developed by Air Force Military Medical University, China (see full Air Force Military Medical University, China pipeline at /company/air-force-military-medical-university-china).

Is Supportive care+Ripertamab also known as anything else?

Supportive care+Ripertamab is also known as Test group 2.

What drug class is Supportive care+Ripertamab in?

Supportive care+Ripertamab belongs to the tyrosine kinase inhibitor class. See all tyrosine kinase inhibitor drugs at /class/tyrosine-kinase-inhibitor.

What development phase is Supportive care+Ripertamab in?

Supportive care+Ripertamab is in Phase 3.

What are the side effects of Supportive care+Ripertamab?

Common side effects of Supportive care+Ripertamab include Hypertension, Fatigue, Nausea.

What does Supportive care+Ripertamab target?

Supportive care+Ripertamab targets KIT, PDGFRA and is a tyrosine kinase inhibitor.

Drug class: All tyrosine kinase inhibitor drugs
Target: All drugs targeting KIT, PDGFRA
Manufacturer: Air Force Military Medical University, China — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Advanced gastrointestinal stromal tumor (GIST) with a KIT or PDGFRA mutation
Indication: Drugs for Advanced or metastatic melanoma with a KIT or PDGFRA mutation
Also known as: Test group 2

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing